SCHEMBL19798441

SCHEMBL19798441

CS(=O)(=O)NCCCOC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
TSHR P16473 2/20 0.48
ALDH1A1 P00352 8/20 0.43
LMNA P02545 5/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 2/20 0.42
HTT P42858 2/20 0.42
KMT2A Q03164 2/20 0.42
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 1/20 0.39
SCN9A Q15858 1/20 0.37
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19798442 0.86 SMN1; SMN2 (0.44) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL19807174 0.85 EPHX2 (0.39) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL19808494 0.84 SMN1; SMN2 (0.43) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL19798445 0.76 MAPK1 (0.56) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL14616638 0.74 SMN1; SMN2 (0.42) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL19798448 0.74 ALDH1A1 (0.43) EPHX2SMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL19798462 0.73 EPHX2 (0.54) EPHX2SCN9ACA12CA2CA7
SCHEMBL19807169 0.73 SMN1; SMN2 (0.38) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL20724740 0.73 SMN1; SMN2 (0.38) SMN1; SMN2TSHRALDH1A1LMNAKDM4E
SCHEMBL19807175 0.72 SMN1; SMN2 (0.36) SMN1; SMN2TSHRALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2019-02-12 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof IDO1, IDO2, TDO2 EPHX2 1124/4885SMN1; SMN2 3655/4885TSHR 2589/4885
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF IDO1, IDO2, TDO2 EPHX2 1124/4885SMN1; SMN2 3655/4885TSHR 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.